Table 2.

Data for patients with adenocarcinoma and performance status 1 or less (n = 14) with user of gefitinib

Patient number	Age (years)	Gender	Performance status	Metastasis to appendicular bone	Pathologic fracture	Solitary or multiple	Radiation	Chemo therapy	Outcome	Survival period (days)
1	42	Female	0	−	−	Multiple	−	+	Dead	898
2	72	Female	1	−	−	Solitary	−	+	Alive	736
3	57	Male	0	−	−	Multiple	+	+	Dead	467
4	68	Female	0	−	−	Multiple	−	+	Alive	903
5	56	Male	1	−	−	Solitary	−	+	Alive	251
6	72	Male	1	+	−	Multiple	+	+	Dead	531
7	66	Male	0	−	–	Multiple	−	+	Dead	427
8	65	Male	0	−	−	Multiple	+	+	Dead	387
9	72	Female	1	−	−	Solitary	+	+	Dead	431
10	69	Male	1	−	−	Multiple	+	+	Alive	491
11	62	Female	1	+	−	Solitary	+	+	Dead	448
12	66	Female	1	−	−	Multiple	−	+	Dead	310
13	66	Male	1	−	−	Multiple	−	+	Alive	621
14	54	Female	1	−	−	Solitary	+	−	Alive	577